Degradative Effect of Nattokinase on Spike Protein of SARS-CoV-2

“In this study, we examined the effect of nattokinase on the S protein of SARS-CoV-2. When cell lysates transfected with S protein were incubated with nattokinase, the S protein was degraded in a dose- and time-dependent manner. Immunofluorescence analysis showed that S protein on the cell surface was degraded when nattokinase was added to the culture medium. Thus, our findings suggest that nattokinase exhibits potential for the inhibition of SARS-CoV-2 infection via S protein degradation.”

—————

Nattokinase decreases plasma levels of fibrinogen, factor VII, and factor VIII in human subjects

“In summary, this study showed that oral administration of nattokinase could be considered as a CVD nutraceutical by decreasing plasma levels of fibrinogen, factor VII, and factor VIII.”

—————

A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles

“…a single-dose of NK administration appears enhancing fibrinolysis and anti-coagulation via several different pathways simultaneously.”

—————

Breaking the vicious loop between inflammation, oxidative stress and coagulation, a novel anti-thrombus insight of nattokinase by inhibiting LPS-induced inflammation and oxidative stress

—————

Nattokinase improves blood flow by inhibiting platelet aggregation and thrombus formation

A pilot study on the serum pharmacokinetics of nattokinase in humans following a single, oral, daily dose

“These results provided the first evidence that nattokinase can be measured directly in the blood of humans.”

Amyloid-degrading ability of nattokinase from Bacillus subtilis natto

—————

Serrapeptase and nattokinase intervention for relieving Alzheimer's disease pathophysiology in rat model

“The present results support our hypothesis that the oral administration of proteolytitc enzymes, SP and/or [nattokinase], would have an effective role in modulating certain factors characterizing AD. Thus, these enzymes may have a therapeutic application in the treatment of AD.”